van Nifterick, Anne M.
Mulder, Danique
Duineveld, Denise J.
Diachenko, Marina
Scheltens, Philip
Stam, Cornelis J.
van Kesteren, Ronald E.
Linkenkaer-Hansen, Klaus
Hillebrand, Arjan
Gouw, Alida A.
Funding for this research was provided by:
Netherlands Organization for Health Research and Development (91218018)
Article History
Received: 23 February 2023
Accepted: 21 April 2023
First Online: 7 May 2023
Competing interests
: Dr. Scheltens is a full time employee of EQT Life Sciences (formerly LSP) and Professor Emeritus at Amsterdam University Medical Centers. He has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell and Green Valley. Within his university affiliation he is global PI of the phase 1b study of AC Immune, Phase 2b study with FUJI-film/Toyama and phase 2 study of UCB. He is past chair of the EU steering committee of the phase 2b program of Vivoryon and the phase 2b study of Novartis Cardiology and presently co-chair of the phase 3 study with NOVO-Nordisk. K.L.-H. is shareholders of Aspect Neuroprofiles BV, which develops physiology-informed prognostic measures for neurodevelopmental disorders. K.L.-H. has filed the patent claim (PCT/NL2019/050167) “Method of determining brain activity”; with priority date 16 March 2018. The other authors declare no competing interests.